Ranked #773 of 8,699 institutional investors
Deep Track Capital, LP
Greenwich, CT
$5.41B
US stock portfolio at live prices · today +$54.1M (+1.01%)
Market closed. Prices as of Nov 20, 7:41 AM ET
- Value at quarter end (Q3 2026)
- $5.94B
- Change from Q2 2026
- −$845.6M (−12.46%)
- Positions
- 64 · 13 new, 11 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $196M of stock. $286M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesGH 7.55%BMRN 7.24%IMVT 5.51%TARS 5.47%MANE 4.37%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| GH Guardant Health, Inc. | 2,805,677 | $408M | 7.55% | Reduced −17% |
| BMRN BioMarin Pharmaceutical Inc. | 6,374,395 | $392M | 7.24% | Added +93% |
| IMVT Immunovant, Inc. | 9,160,801 | $298M | 5.51% | Reduced −2% |
| TARS Tarsus Pharmaceuticals, Inc. | 3,806,768 | $296M | 5.47% | Added +4% |
| MANE Veradermics Inc | 1,900,000 | $236M | 4.37% | Reduced −5% |
| GMAB Genmab A/S | 4,182,689 | $215M | 3.97% | Reduced −26% |
| PCVX Vaxcyte, Inc. | 3,513,069 | $205M | 3.79% | Reduced −18% |
| INSM Insmed Incorporated | 1,350,000 | $195M | 3.61% | New |
| VERA Vera Therapeutics, Inc. | 7,000,000 | $187M | 3.46% | Added +75% |
| UTHR United Therapeutics Corporation | 300,040 | $168M | 3.10% | Added +143% |
| COAG Hemab Therapeutics Holdings, Inc. | 3,587,796 | $143M | 2.64% | Reduced −0% |
| LBRX LB Pharmaceuticals Inc | 3,352,804 | $134M | 2.48% | Unchanged |
| MAZE Maze Therapeutics, Inc. | 4,083,969 | $132M | 2.45% | Added +9% |
| OCUL Ocular Therapeutix, Inc. | 21,939,625 | $129M | 2.38% | Added +11% |
| GRAL GRAIL, Inc. | 1,104,200 | $116M | 2.14% | Reduced −40% |
| AXSM Axsome Therapeutics, Inc. | 800,000 | $109M | 2.01% | Added +14% |
| CMPS COMPASS Pathways plc | 12,161,496 | $105M | 1.94% | Unchanged |
| ORKA Oruka Therapeutics, Inc. | 1,069,774 | $104M | 1.93% | Reduced −44% |
| TNGX Tango Therapeutics, Inc. | 4,500,000 | $102M | 1.89% | Added +7% |
| MLTX MoonLake Immunotherapeutics | 8,105,290 | $89.4M | 1.65% | Added +16% |
| GPCR Structure Therapeutics Inc. | 5,000,000 | $85.6M | 1.58% | Added +5% |
| NRIX Nurix Therapeutics, Inc. | 6,000,000 | $81.6M | 1.51% | Reduced −22% |
| COGT Cogent Biosciences, Inc. | 2,500,000 | $69.3M | 1.28% | Added +25% |
| BBIO BridgeBio Pharma, Inc. | 885,882 | $69.3M | 1.28% | New |
| CLDX Celldex Therapeutics, Inc. | 2,125,532 | $59.4M | 1.10% | Reduced −28% |
| WGS GeneDx Holdings Corp. | 1,200,000 | $59.1M | 1.09% | Added +71% |
| LTGO Latigo Biotherapeutics, Inc. | 4,408,322 | $58.4M | 1.08% | New |
| VRDN Viridian Therapeutics, Inc. | 1,711,030 | $53.8M | 0.99% | Reduced −52% |
| ATTO Attovia Therapeutics, Inc. | 3,207,138 | $50.0M | 0.92% | New |
| EWTX Edgewise Therapeutics, Inc. | 1,148,817 | $47.3M | 0.87% | New |
| BLLN BillionToOne, Inc. | 500,000 | $45.1M | 0.83% | New |
| VSTM Verastem, Inc. | 5,740,850 | $39.4M | 0.73% | Unchanged |
| BCAX Bicara Therapeutics Inc. | 4,100,000 | $37.4M | 0.69% | Unchanged |
| ANIP ANI Pharmaceuticals, Inc. | 500,000 | $34.6M | 0.64% | New |
| HROW Harrow, Inc. | 1,069,000 | $34.3M | 0.64% | Added +10% |
| MBX MBX Biosciences, Inc. | 640,000 | $34.2M | 0.63% | Reduced −63% |
| ACRS Aclaris Therapeutics, Inc. | 9,345,000 | $32.7M | 0.60% | Unchanged |
| ALMS Alumis Inc. | 7,469,746 | $32.3M | 0.60% | Added +18% |
| CRMD CorMedix Inc. | 6,274,076 | $31.9M | 0.59% | Unchanged |
| NBIX Neurocrine Biosciences, Inc. | 200,000 | $31.3M | 0.58% | New |
| DFTX Definium Therapeutics, Inc. | 1,000,000 | $29.5M | 0.55% | Reduced −64% |
| ALT Altimmune, Inc. | 19,250,000 | $27.1M | 0.50% | Unchanged |
| GENB Generate Biomedicines, Inc. | 2,507,449 | $26.0M | 0.48% | Added +88% |
| OBX Obsidian Therapeutics, Inc. | 2,120,050 | $25.8M | 0.48% | New |
| CRVS Corvus Pharmaceuticals, Inc. | 2,491,939 | $24.9M | 0.46% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 3,610,000 | $24.4M | 0.45% | Unchanged |
| SLDB Solid Biosciences Inc. | 3,565,062 | $23.0M | 0.42% | Unchanged |
| BEAM Beam Therapeutics Inc. | 1,000,000 | $20.9M | 0.39% | Unchanged |
| MNKD MannKind Corporation | 5,030,522 | $19.9M | 0.37% | Reduced −16% |
| XENE Xenon Pharmaceuticals Inc. | 500,000 | $18.8M | 0.35% | New |
| XNCR Xencor, Inc. | 540,000 | $18.4M | 0.34% | Reduced −9% |
| STTK Shattuck Labs, Inc. | 3,706,734 | $16.9M | 0.31% | Unchanged |
| OLMA Olema Oncology, Inc. | 2,109,951 | $15.1M | 0.28% | Added +41% |
| XFOR X4 Pharmaceuticals, Inc. | 4,501,684 | $13.3M | 0.25% | Reduced −23% |
| IPSC Century Therapeutics, Inc. | 9,462,645 | $12.5M | 0.23% | Unchanged |
| DSGN Design Therapeutics, Inc. | 1,323,986 | $12.3M | 0.23% | New |
| NKTR Nektar Therapeutics | 300,000 | $9.8M | 0.18% | Unchanged |
| MPLT MapLight Therapeutics, Inc. | 1,318,101 | $8.5M | 0.16% | New |
| ENTA Enanta Pharmaceuticals, Inc. | 1,000,000 | $8.0M | 0.15% | Reduced −31% |
| KARD Kardigan, Inc. | 600,000 | $7.5M | 0.14% | Unchanged |
| RXST RxSight, Inc. | 1,230,566 | $5.7M | 0.10% | New |
| PMN ProMIS Neurosciences, Inc. | 740,117 | $2.4M | <0.1% | Reduced −11% |
| CNTX Context Therapeutics Inc. | 7,419,355 | $1.3M | <0.1% | Unchanged |
| ALGS Aligos Therapeutics, Inc. | 444,110 | $555K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | 825,000 | $122M |
| IONS Ionis Pharmaceuticals, Inc. | 2,200,000 | $59.9M |
| PSNL Personalis, Inc. | 4,000,000 | $58.9M |
| CYTK Cytokinetics, Incorporated | 700,000 | $36.0M |
| DYN Dyne Therapeutics, Inc. | 1,500,000 | $24.0M |
| IMMX Immix Biopharma, Inc. | 2,775,000 | $19.5M |
| KURA Kura Oncology, Inc. | 1,978,565 | $14.5M |
| ELVN Enliven Therapeutics, Inc. | 225,000 | $10.4M |
| IMCR Immunocore Holdings plc | 311,218 | $8.3M |
| KLRA Kailera Therapeutics, Inc. | 700,000 | $8.1M |
| IVA Inventiva S.A. | 800,000 | $2.8M |